US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

crane

186.56

-0.0250-0.01%

Volume:33.43K

Turnover:6.22M

Market Cap:10.73B

PE:32.37

High:187.18

Open:185.00

Low:184.72

Close:186.58

Loading ...

Overview Company News Filings

Curis Provides Fourth Quarter 2024 Business Update

Press Release: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Press Release: Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today

Is Crane Company (NYSE:CR) One of the Best Stocks to Buy According to Billionaire Mario Gabelli?

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

CR Construction Group Holdings Full Year 2024 Earnings: EPS: HK$0.11 (vs HK$0.14 in FY 2023)

Simply Wall St.

BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum

ACCESS Newswire

Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

ACCESS Newswire

CR Construction Group Announces Final Dividend for 2024

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CR/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CR\",,,,,undefined,":{"symbol":"CR","market":"US","secType":"STK","nameCN":"crane","latestPrice":186.555,"timestamp":1749740118773,"preClose":186.58,"halted":0,"volume":33431,"delay":0,"floatShares":48719860,"shares":57501189,"eps":5.763835,"marketStatus":"Trading","change":-0.025,"latestTime":"06-12 10:55:20 EDT","open":185,"high":187.18,"low":184.72,"amount":6221203.20635,"amplitude":0.013185,"askPrice":186.77,"askSize":7,"bidPrice":186.16,"bidSize":29,"shortable":3,"etf":0,"ttmEps":5.763835,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749758400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":186.58,"dividendRate":0.004529,"preHourTrading":{"tag":"盘前","latestPrice":186.95,"preClose":186.58,"latestTime":"09:12 EDT","volume":4,"amount":747.8,"timestamp":1749733963617},"postHourTrading":{"tag":"盘后","latestPrice":186.61,"preClose":186.61,"latestTime":"19:43 EDT","volume":7918,"amount":1477584.58,"timestamp":1749685428440},"volumeRatio":0.377115,"impliedVol":0.2589,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CR\",,,,,undefined,":{"symbol":"CR","floatShares":48719860,"roa":"8.85%","roe":"18.17%","lyrEps":5.152097,"volumeRatio":0.377115,"shares":57501189,"dividePrice":0.845,"high":187.18,"amplitude":0.013185,"preClose":186.58,"low":184.72,"week52Low":127.04,"pbRate":"6.11","psRate":"4.92","week52High":191,"institutionHeld":0.6875,"latestPrice":186.555,"committee":0.611111,"eps":5.763835,"divideRate":0.004529,"volume":33431,"delay":0,"ttmEps":5.763835,"open":185,"prevYearClose":151.75,"prevWeekClose":177.68,"prevMonthClose":171.4,"prevQuarterClose":153.18,"fiveDayClose":174.89,"twentyDayClose":175.3,"sixtyDayClose":151.65},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CR\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523946600","title":"Curis Provides Fourth Quarter 2024 Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946600","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946600?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU. Orphan Drug Designation for PCNSL granted in both US and EU. Management to host conference call today at 8:30 a.m. ET. LEXINGTON, Mass., March 31, 2025 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of emavusertib , an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2024.Curis successfully concluded meetings with both the U.S. Food and Drug Administration  and the Committee for Medicinal Products for Human Use of the European Medicines Agency  on the suitability of using the ongoing TakeAim Lymphoma study  to support a potential accelerated approval path in PCNSL.6 patients had change in tumor burden data available as of data cutoff;The Company initiated a Phase 1 clinical study of emavusertib in combination with venetoclax and azacitidine  in frontline AML . ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/curis-provides-fourth-quarter-2024-120000997.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/curis-provides-fourth-quarter-2024-120000997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","BK4211","CMA","BK4589","BK4161","BK4139","BK4585","PR","CRIS","BK4588","CR","BK4207"],"gpt_icon":0},{"id":"2522430524","title":"Press Release: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522430524","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522430524?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:00","pubTimestamp":1743159600,"startTime":"0","endTime":"0","summary":"- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin -Unresponsive Non-Muscle Invasive Bladder Cancer  -. - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Nave  and BCG-Exposed  NMIBC -. - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress -. IRVINE, Calif., March 28, 2025  -- CG Oncology, Inc. , a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business updates.Any Time in High-Risk  BCG-Unresponsive NMIBC with carcinoma in situ. reached but exceeds 28 months as of the data cutoff of Januar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4135","BK4585","LU0058720904.USD","IE00B19Z3581.USD","US12M.BOND","BK4161","BK4196","US7Y.BOND","US6M.BOND","CI","IE00B3QW5Z07.USD","BK4588","US5Y.BOND","BK4139","IE00BGHQF748.EUR","BK4225","BK4203","US3Y.BOND","US10Y.BOND","LU1261432733.SGD","BCG","US30Y.BOND","HR","IE0002270589.USD","CR","CGON","LU0868494617.USD","IE00B19Z3B42.SGD","US2Y.BOND","LU1059921491.USD","CG","LU0289739699.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2522558078","title":"Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522558078","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522558078?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"– Initial clinical activity in a PD-1 resistant population, with an ORR almost three times higher than historical PD-1 rechallenge response rates, with data still maturing –。– One durable complete response in a Merkel Cell Carcinoma  patient and two partial responses , including one in a second MCC patient and one in a microsatellite instability-high  Colorectal Cancer  patient, all of whom were previously treated with and progressed on immunotherapy –。– All PD-1 resistant “hot” tumor patients with tumor shrinkage remain on study, suggesting potential for deepening responses over time –。The Phase 1 dose expansion trial is a multi-center, open-label, dose expansion study evaluating solnerstotug as monotherapy and in combination withLibtayo , Regeneron’s PD-1 inhibitor, in both a basket of “hot” tumorsthat typically respond to immunotherapy but have progressed on prior PD-1 therapy and a single “cold” tumor histology  that is typically unresponsive to immunotherapy.At the time of this da","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sensei-biotherapeutics-reports-favorable-preliminary-200500147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","CRC","RCC","SITC","LU1169589451.USD","CRS","BK4139","BK4080","LU0053666078.USD","BK4107","PD","CR","BK4213","BK4161","IE00B19Z4B17.USD","BK4006","LU0456854461.SGD","BK4588","SD","IE00B66KJ199.SGD","L","LU2065731478.USD","LU1169590202.USD","BK4585","BK4231","LU0266512127.USD","MSS","PR","BK4023","SNSE","BK4113","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2522539232","title":"Press Release: Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539232","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539232?lang=en_us&edition=fundamental","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"- Three INDs cleared by US FDA for TYRA's proprietary precision small molecules -. - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer , BEACH301 for pediatric achondroplasia  and SURF301 for metastatic urothelial cancer  -. - Cash, cash equivalents, and marketable securities of $341.4 million at YE 2024; runway through at least 2027 -. \"2024 was a momentous year for TYRA and the patient communities we serve, highlighted by the positive interim results from our SURF301 study, which demonstrated a combination of high anti-tumor activity with favorable tolerability results in very sick, heavily pre-treated cancer patients. Importantly, the oncology doses tested in SURF301 are significantly higher than those to be tested in BEACH301, giving us confidence as we advance TYRA-300 in ACH,\" said Todd Harris, CEO of TYRA. \"Our conviction in TYRA-300 has never been stronger and we are working diligently to advance this potential b","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","CR","BK4195","ACH","HCC","BK4563","TYRA","BK4166","BK4153","BK4211","BK4161","PR","QD","BK4006","BK4213","BK4139","BK4503"],"gpt_icon":0},{"id":"2522306967","title":"Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225","url":"https://stock-news.laohu8.com/highlight/detail?id=2522306967","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522306967?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:45","pubTimestamp":1743079500,"startTime":"0","endTime":"0","summary":"- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models. - ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model. - Initial ATNM-400 preclinical data to be presented at AACR including results in Pluvicto resistant prostate cancer models. ATNM-400 selectively binds to prostate cancer cells, undergoes rapid internalization, and induces dose-depen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-atnm-400-124500358.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-atnm-400-124500358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NCI","BK4202","HMA","BK4139","ATNM","BK4161","CR"],"gpt_icon":0},{"id":"2522708653","title":"CERo Therapeutics Holdings, Inc.  Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522708653","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522708653?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:15","pubTimestamp":1743077700,"startTime":"0","endTime":"0","summary":"Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology  conference; Continues to be on track to dose first patient in first half of 2025. SOUTH SAN FRANSCISCO, Calif., March 27, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has received positive review from the U.S. Food and Drug Administration  on an amendment to its IND around Chemistry, Manufacturing and Controls , which marks completion of the Company’s final commitment to FDA prior to initiating patient dosing and shortens the manufacturing timeline by about a week. With this completion, the Company is on track to meet its anticipated timeline of dosing initial subjects during the first half of 2025.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-poised-121500919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","CMC","BK4161","IE00BKVL7J92.USD","BK4218","LU0971096721.USD","PK","IE00BZ1G4Q59.USD","LU1363072403.SGD","LU0170899867.USD","ORR","IE00B1BXHZ80.USD","BK4181","CERO","LU0267386448.USD","LU0882574139.USD","CEROW","LU0149725797.USD","CR","IE00BHPRN162.USD"],"gpt_icon":0},{"id":"2522537175","title":"Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537175","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537175?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"Treatment with itolizumab did not improve complete or overall response rates at Day 29. Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival. Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025. Management will host a conference call and webcast today at 8:30 am ET. \"The longer-term outcomes are important,\" said Dr. John Koreth, Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School. \"There are no approvals in first-line therapy for aGVHD, and no drug candidates have been able to demonstrate efficacy beyond four weeks. To demonstrate statistical significance in pre-specified endpoints of duration of complete response and failure-free survival, compared to standard of care therapy, is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/equillium-announces-results-phase-3-110000303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","CR","EQ","ITT","HST","LU0053671581.USD","BK4139","BK4181","BK4568","BK4161","BK4218","LU0054578231.USD","BK4585","ORR"],"gpt_icon":0},{"id":"2522429371","title":"Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522429371","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522429371?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"Breakthrough Therapy designation and meeting request to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025. LA JOLLA, Calif., March 27, 2025----Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2024, as well as corporate and clinical highlights.Announced topline data from the Phase 3 EQUATOR study in first-line acute graft-versus-host disease  demonstrating a favorable safety and tolerability profile, and clinically meaningful longer-term outcomes. There was no meaningful difference in complete response  and overall response rate  at Day 29 between itolizumab patients and placebo patients, but statistical significance and/or clinically meaningful benefit in longer term outcomes were achieved by itolizumab in the following measurements","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/equillium-reports-fourth-quarter-full-110000383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","ORR","BK4139","EQ","CR","BK4161"],"gpt_icon":0},{"id":"2522361927","title":"Junshi Biosciences Announces Toripalimab’s Approval in Singapore","url":"https://stock-news.laohu8.com/highlight/detail?id=2522361927","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522361927?lang=en_us&edition=fundamental","pubTime":"2025-03-27 09:00","pubTimestamp":1743037200,"startTime":"0","endTime":"0","summary":"SHANGHAI, March  26, 2025  (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/27/3050235/0/en/Junshi-Biosciences-Announces-Toripalimab-s-Approval-in-Singapore.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","CR","BK4161","HCC","RCC"],"gpt_icon":0},{"id":"2522880537","title":"Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2522880537","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522880537?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:45","pubTimestamp":1742993100,"startTime":"0","endTime":"0","summary":"- Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical data expected in 2025 supporting each addressable market. - Presentation follows Investor KOL Event and Company Update on March 25th. NEW YORK, March 26, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. , a pioneer in the development of targeted radiotherapies, announced it will be presenting a business update today at Trump Mar-a-Lago Club, Florida. This presentation follows an Investor KOL Call and Company Update hosted by Actinium on Tuesday, March 25th highlighting its revitalized clinical programs and expanded market opportunities. Actinium's Investor KOL Call and Company Update can be accessed for replay here.Generate clinical data in first non-malignant indication from sickle cell disease allogeneic stem cell transplant trial at Columbia University","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-present-business-trump-124500258.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-present-business-trump-124500258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","BK4139","ATNM","HMA","BK4202","BK4161","NCI"],"gpt_icon":0},{"id":"2522882578","title":"Is Crane Company (NYSE:CR) One of the Best Stocks to Buy According to Billionaire Mario Gabelli?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522882578","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522882578?lang=en_us&edition=fundamental","pubTime":"2025-03-26 01:03","pubTimestamp":1742922236,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Stocks to Buy According to Billionaire Mario Gabelli. In this article, we are going to take a look at where Crane Company  stands against other stocks to buy according to billionaire Mario Gabelli.GAMCO Investors, formerly known as Gabelli Asset Management Company, is an investment firm with its headquarters in Rye, New York. The company has expertise in providing investment advice and brokerage services to mutual funds, institutional clients, and select investors. It was founded and is majority-owned by Mario Gabelli. Mr. Gabelli is the Chairman and Chief Executive Officer of GAMCO Investors, Inc.With respect to value, the company’s investment approach revolves around utilizing fundamental, bottom-up research to spot securities selling below their intrinsic value. Furthermore, the investment firm seeks to identify mispriced companies possessing healthy businesses and the presence of a catalyst that will surface value. The firm’s investment teams","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crane-company-nyse-cr-one-170356546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NYSE","GCAD","GGRW","BK4161","CR"],"gpt_icon":0},{"id":"2522022501","title":"Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022501","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022501?lang=en_us&edition=fundamental","pubTime":"2025-03-25 18:00","pubTimestamp":1742896800,"startTime":"0","endTime":"0","summary":"- Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning. - Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin to highlight Actimab-A clinical results, mutation agnostic mechanism and backbone therapy potential. - Clinical proof of concept data from frontline AML trial under NCI CRADA, Actimab-A solid tumor program with PD-1 checkpoint inhibitors and Iomab-ACT commercial CAR-T trial together with other expected 2025 milestones to be outlined. - Actinium to highlight manufacturing infrastructure development activity to support revitalized clinical programs. Actinium's company update will highlight the 3 separate potential multi-billion-dollar blockbuster market opportunities being pursued with its targeted radiotherapies including the following:. - Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies including AML and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-kol-investor-100000655.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-host-kol-investor-100000655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CR","ATNM","BK4218","HMA","BK4161","BK4202","BK4181","BK4139","ET","HST","NCI","BK4581","BK4585","BK4588","BK4590","BK4144","KOL","BK4561"],"gpt_icon":0},{"id":"2522707005","title":"Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707005","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707005?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:15","pubTimestamp":1742847300,"startTime":"0","endTime":"0","summary":"NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. , a pioneer in the development of targeted radiotherapies,today announced it has entered into an agreement for the supply of Actinium-225  with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials.Targeted radiotherapies using Ac-225 have shown great promise in the treatment of cancer. The radioisotope releases powerful alpha particles with high energy and low penetration depth, enabling precise targeting of tumor cells, including hard-to-reach micrometastases, while minimizing effects on surrounding healthy tissue. Actimab-A is an Ac-225 based radiotherapy agent, directed against CD33, a receptor overexpressed in patients with acute myeloid leukemia  and other myeloid indications.E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-supply-agreement-201500023.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-supply-agreement-201500023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4202","NCI","BK4161","BK4139","HMA","CR","ATNM"],"gpt_icon":0},{"id":"2521747112","title":"Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747112","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747112?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response exceeds 28 months and is ongoing –– No close contact precautions needed post creto","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047782/0/en/Cretostimogene-Grenadenorepvec-Data-Continues-to-Demonstrate-Best-in-Class-Durability-of-Response-as-well-as-Consistent-and-Compelling-Safety-and-Efficacy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","BK4139","BK4161","BK4135","BCG","CR"],"gpt_icon":0},{"id":"2521260564","title":"CR Construction Group Holdings Full Year 2024 Earnings: EPS: HK$0.11 (vs HK$0.14 in FY 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2521260564","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521260564?lang=en_us&edition=fundamental","pubTime":"2025-03-22 08:06","pubTimestamp":1742601960,"startTime":"0","endTime":"0","summary":"CR Construction Group Holdings ( HKG:1582 ) Full Year 2024 Results Key Financial Results Revenue: HK$6.07b (up 11% from...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/capital-goods/hkg-1582/cr-construction-group-holdings-shares/news/cr-construction-group-holdings-full-year-2024-earnings-eps-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CR","01582"],"gpt_icon":0},{"id":"2521200024","title":"BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2521200024","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521200024?lang=en_us&edition=fundamental","pubTime":"2025-03-21 15:20","pubTimestamp":1742541600,"startTime":"0","endTime":"0","summary":"BioInvent International AB  , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that one of the company's lead program; BI-1808 as monotherapy in Cutaneous T Cell Lymphoma  will be presented at the 16th Annual T-Cell Lymphoma Forum held March 20-22, 2025 in La Jolla, California.The data, previously disclosed in a press release in September 2024, will be featured in a poster presentation highlighting the early efficacy of BI-1808 monotherapy in the ongoing Phase 2a dose expansion study in CTCL. So far three partial responses  and one stable disease  out of four evaluable patients have been reported. The Company anticipates reporting additional data from the study in mid-2025.BI-1808, a first-in-class anti-TNFR2 antibody, was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration  for the treatment of TCL.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioinvent-anti-tnfr2-antibody-bi-072000423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4213","CR","BOVNF","SD","FET","PR","BK4179","BK4161"],"gpt_icon":0},{"id":"2521151496","title":"Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521151496","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521151496?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in Acute Myeloid Leukemia  with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 --. -- Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009  in r/r AML -- Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 --. Announced Positive Outcome of Interim Analysis for Phase 3 REGAL Trial of GPS in AML: The interim futility, efficacy, and safety analysis was designed to assess whether the therap","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4232","BK4161","ALL","ODD","BK4202","BK4218","SLS","BK4097","BK4585","BK4109","R","LU2463526074.USD","LU1699723380.USD","OS","BK4183","PR","ORR","ASH","BK4213","LU2355687059.USD","INN","BK4181","LU0985320562.USD","NCI","LU1571399168.USD","BK4533","BK4588","BK4107","CR","BK4022"],"gpt_icon":0},{"id":"2521493824","title":"Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2521493824","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521493824?lang=en_us&edition=fundamental","pubTime":"2025-03-21 02:26","pubTimestamp":1742495195,"startTime":"0","endTime":"0","summary":"On Thursday, Aptevo Therapeutics  announced two additional frontline Acute Myeloid Leukemia  patients have achieved remission within 30 days of treatment in the RAINIER dose optimization trial of mipletamig in combination with standard of care for patients unfit for intensive chemotherapy.9 of 10 frontline patients across two trials achieved remission when receiving the triplet combination of mipletamig + venetoclax + azacitidine .Notably, no cytokine release syndrome  has been reported in the RAINIER trial to date.Together with the addition of these interim Cohort 2 results, mipletamig has achieved a compelling overall remission rate of 90% among frontline patients, outperforming the doublet remission rate from a venetoclax + azacitidine-only study of 66%.In December 2024, Aptevo Therapeutics announced that 100% of patients achieved remission within 30 days in Cohort 1 of the RAINIER frontline acute myeloid leukemia  Phase 1b trial, including two patients who experienced complete remi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aptevo-therapeutics-says-two-additional-182635823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","IE0031619046.USD","CR","BK4139","BK4006","LU2065731478.USD","IE00B7SZL793.SGD","CRS","APVO","SSI","IE00B19Z4B17.USD","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2520452538","title":"RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2520452538","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520452538?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:35","pubTimestamp":1742474100,"startTime":"0","endTime":"0","summary":"Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care. Triplet Combination with mipletamig continues to outperform doublet combination benchmark. No Cytokine Release Syndrome  has been observed in the RAINIER trial to date. The data builds on previously reported favorable outcomes from RAINIER's Cohort 1 and the completed dose expansion trial where 100% of frontline patients achieved remission. Together with the addition of these interim Cohort 2 results, mipletamig has achieved a compelling overall remission rate of 90% among frontline patients. This outperforms the doublet remission* rate from a venetoclax + azacitidine only study, of 66%. Additionally, the frontline patient triplet therapy CR rate of 70% outperforms the CR rate from a venetoclax + azacitidine only study of 36% .Thus far, all RAINIER patients who achieved remission remain in remission.Two patients achieved remission withing 30 days o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rainier-trial-data-two-additional-123500697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","IE0031619046.USD","LU2065731478.USD","CRS","BK4139","APVO","IE00B66KJ199.SGD","CR","IE00B7SZL793.SGD","BK4161","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2520455465","title":"CR Construction Group Announces Final Dividend for 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2520455465","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520455465?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:13","pubTimestamp":1742472791,"startTime":"0","endTime":"0","summary":"The latest update is out from CR Construction Group Holdings Limited ( ($HK:1582) ). CR Construction Group Holdings Limited has announced a final o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cr-construction-group-announces-final-dividend-for-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cr-construction-group-announces-final-dividend-for-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CR","BK4161"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CR\",params:#limit:5,,,undefined,":[{"date":"2025-05-30","symbol":"CR","amount":0.23,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-30","defaultRemindTime":1748611800000,"name":"crane","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-11","payableDate":"2025-05-30","currency":"USD","dateTimestamp":1748577600000,"payDate":"2025-06-11"},{"market":"US","date":"2025-04-28","symbol":"CR","fiscalQuarterEnding":"2025/03","expectedEps":1.29,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745812800000,"reportTimeType":"post","actualEps":1.39},{"date":"2025-02-28","symbol":"CR","amount":0.23,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-28","defaultRemindTime":1740753000000,"name":"crane","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-12","payableDate":"2025-02-28","currency":"USD","dateTimestamp":1740718800000,"payDate":"2025-03-12"},{"market":"US","date":"2025-01-27","symbol":"CR","fiscalQuarterEnding":"2024/12","expectedEps":1.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1737954000000,"reportTimeType":"post","actualEps":1.26},{"date":"2024-11-29","symbol":"CR","amount":0.205,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-29","defaultRemindTime":1732890600000,"name":"crane","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-11","payableDate":"2024-11-29","currency":"USD","dateTimestamp":1732856400000,"payDate":"2024-12-11"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CR\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-24","recordDate":"2017-02-28","paymentDate":"2017-03-09","value":0.33,"currency":"USD"},{"executeDate":"2017-05-26","recordDate":"2017-05-31","paymentDate":"2017-06-09","value":0.33,"currency":"USD"},{"executeDate":"2017-08-29","recordDate":"2017-08-31","paymentDate":"2017-09-08","value":0.33,"currency":"USD"},{"executeDate":"2017-11-29","recordDate":"2017-11-30","paymentDate":"2017-12-08","value":0.33,"currency":"USD"},{"executeDate":"2018-02-27","recordDate":"2018-02-28","paymentDate":"2018-03-09","value":0.35,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.7778,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7778,"analysts":9,"updateTime":1745985600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CR","date":"2025-06-10","current":31.734855,"percent":0.742067,"low":8.74154,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"high":224.415426,"avg":34.005267,"sd":39.659472,"marketCap":10694646142},"quantilePoints":[{"date":"2020-06-12","current":28.05608,"twenty":14.741964,"median":19.280168,"eighty":26.565059,"marketCap":3189976299},{"date":"2020-06-19","current":28.040782,"twenty":14.741964,"median":19.30144,"eighty":26.931579,"marketCap":3188236945},{"date":"2020-06-26","current":28.73428,"twenty":14.741964,"median":19.376127,"eighty":27.12269,"marketCap":3267087686},{"date":"2020-07-02","current":29.529764,"twenty":14.741964,"median":19.392132,"eighty":27.321969,"marketCap":3357534124},{"date":"2020-07-10","current":27.913301,"twenty":14.741964,"median":19.430021,"eighty":27.459735,"marketCap":3173742323},{"date":"2020-07-17","current":30.717889,"twenty":14.741964,"median":19.444135,"eighty":27.610101,"marketCap":3492623996},{"date":"2020-07-24","current":30.891264,"twenty":14.741964,"median":19.472413,"eighty":27.833259,"marketCap":3512336681},{"date":"2020-07-31","current":87.533402,"twenty":14.74899,"median":19.495965,"eighty":27.94019,"marketCap":3282502591},{"date":"2020-08-07","current":93.258585,"twenty":14.767286,"median":19.525503,"eighty":28.009625,"marketCap":3497196945},{"date":"2020-08-14","current":94.264361,"twenty":14.787765,"median":19.544175,"eighty":28.04746,"marketCap":3534913520},{"date":"2020-08-21","current":87.719084,"twenty":14.813662,"median":19.570486,"eighty":28.081529,"marketCap":3289465651},{"date":"2020-08-28","current":90.040104,"twenty":14.83771,"median":19.594842,"eighty":28.170784,"marketCap":3376503903},{"date":"2020-09-04","current":88.260655,"twenty":14.871894,"median":19.605519,"eighty":28.267865,"marketCap":3309774577},{"date":"2020-09-11","current":84.237554,"twenty":14.936445,"median":19.626415,"eighty":28.310525,"marketCap":3158908274},{"date":"2020-09-18","current":81.978428,"twenty":15.011846,"median":19.656053,"eighty":28.373051,"marketCap":3074191042},{"date":"2020-09-25","current":76.779343,"twenty":15.041272,"median":19.669528,"eighty":28.409968,"marketCap":2879225359},{"date":"2020-10-02","current":76.965025,"twenty":15.066218,"median":19.682881,"eighty":28.47471,"marketCap":2886188419},{"date":"2020-10-09","current":80.137085,"twenty":15.081973,"median":19.70422,"eighty":28.560476,"marketCap":3005140696},{"date":"2020-10-16","current":84.253027,"twenty":15.124703,"median":19.713849,"eighty":28.62779,"marketCap":3159488529},{"date":"2020-10-23","current":85.320697,"twenty":15.162424,"median":19.729877,"eighty":28.703268,"marketCap":3199526125},{"date":"2020-10-30","current":136.527006,"twenty":15.223621,"median":19.752233,"eighty":28.737446,"marketCap":2948983334},{"date":"2020-11-06","current":142.122596,"twenty":15.260409,"median":19.772138,"eighty":28.792366,"marketCap":3069848070},{"date":"2020-11-13","current":165.258207,"twenty":15.260409,"median":19.790516,"eighty":28.85843,"marketCap":3569577265},{"date":"2020-11-20","current":177.390952,"twenty":15.260409,"median":19.802914,"eighty":28.931965,"marketCap":3831644553},{"date":"2020-11-27","current":191.003299,"twenty":15.260409,"median":19.824132,"eighty":28.993533,"marketCap":4125671266},{"date":"2020-12-04","current":198.293707,"twenty":15.260409,"median":19.834923,"eighty":29.072788,"marketCap":4283144070},{"date":"2020-12-11","current":204.884666,"twenty":15.277405,"median":19.845593,"eighty":29.204431,"marketCap":4425508783},{"date":"2020-12-18","current":208.059087,"twenty":15.319129,"median":19.880269,"eighty":29.408025,"marketCap":4494076277},{"date":"2020-12-24","current":206.848503,"twenty":15.339718,"median":19.900532,"eighty":29.534806,"marketCap":4467927656},{"date":"2020-12-31","current":208.919947,"twenty":15.365764,"median":19.915811,"eighty":29.796111,"marketCap":4512670852},{"date":"2021-01-08","current":218.147289,"twenty":15.386249,"median":19.927575,"eighty":30.133245,"marketCap":4711981450},{"date":"2021-01-15","current":217.178822,"twenty":15.463133,"median":19.955186,"eighty":30.348098,"marketCap":4691062553},{"date":"2021-01-22","current":216.990509,"twenty":15.518993,"median":19.983043,"eighty":30.612845,"marketCap":4686994990},{"date":"2021-01-29","current":24.296226,"twenty":15.546124,"median":20.000911,"eighty":30.612845,"marketCap":4397616921},{"date":"2021-02-05","current":26.22567,"twenty":15.604175,"median":20.036867,"eighty":30.612845,"marketCap":4746846277},{"date":"2021-02-12","current":26.752174,"twenty":15.64869,"median":20.047071,"eighty":30.612845,"marketCap":4842143473},{"date":"2021-02-19","current":27.198418,"twenty":15.679949,"median":20.069656,"eighty":30.612845,"marketCap":4922913657},{"date":"2021-02-26","current":26.948508,"twenty":15.757032,"median":20.101665,"eighty":30.612845,"marketCap":4877680001},{"date":"2021-03-05","current":28.764142,"twenty":16.078184,"median":20.131636,"eighty":30.613864,"marketCap":5206309765},{"date":"2021-03-12","current":30.119103,"twenty":16.146147,"median":20.17181,"eighty":30.613864,"marketCap":5451557630},{"date":"2021-03-19","current":30.222173,"twenty":16.146147,"median":20.191936,"eighty":30.619304,"marketCap":5470213373},{"date":"2021-03-26","current":30.595804,"twenty":16.155113,"median":20.208951,"eighty":30.618171,"marketCap":5537840438},{"date":"2021-04-01","current":30.605466,"twenty":16.155113,"median":20.23058,"eighty":30.618171,"marketCap":5539589413},{"date":"2021-04-09","current":30.682769,"twenty":16.146147,"median":20.256725,"eighty":30.624072,"marketCap":5553581220},{"date":"2021-04-16","current":30.421872,"twenty":16.146147,"median":20.279169,"eighty":30.659957,"marketCap":5506358873},{"date":"2021-04-23","current":30.705316,"twenty":16.146147,"median":20.301119,"eighty":30.68362,"marketCap":5557662164},{"date":"2021-04-30","current":30.296255,"twenty":16.155113,"median":20.344302,"eighty":30.707893,"marketCap":5483622187},{"date":"2021-05-07","current":25.569844,"twenty":16.155113,"median":20.376409,"eighty":30.707893,"marketCap":5794126672},{"date":"2021-05-14","current":25.399722,"twenty":16.199938,"median":20.42789,"eighty":30.707893,"marketCap":5755577038},{"date":"2021-05-21","current":24.309395,"twenty":16.338001,"median":20.491036,"eighty":30.707893,"marketCap":5508508935},{"date":"2021-05-28","current":24.613553,"twenty":16.445582,"median":20.602521,"eighty":30.707893,"marketCap":5577431007},{"date":"2021-06-04","current":24.257843,"twenty":16.445582,"median":20.635149,"eighty":30.707893,"marketCap":5496827228},{"date":"2021-06-11","current":23.729434,"twenty":16.445582,"median":20.724193,"eighty":30.707893,"marketCap":5377089732},{"date":"2021-06-18","current":22.296285,"twenty":16.445582,"median":20.784488,"eighty":30.707893,"marketCap":5052338277},{"date":"2021-06-25","current":23.739744,"twenty":16.445582,"median":20.844829,"eighty":30.707893,"marketCap":5379426073},{"date":"2021-07-02","current":24.116075,"twenty":16.637435,"median":20.901381,"eighty":30.707893,"marketCap":5464702534},{"date":"2021-07-09","current":24.409922,"twenty":17.169936,"median":20.986777,"eighty":30.707893,"marketCap":5531288264},{"date":"2021-07-16","current":23.314439,"twenty":17.256001,"median":21.022105,"eighty":30.707893,"marketCap":5283051990},{"date":"2021-07-23","current":23.799029,"twenty":17.256001,"median":21.108637,"eighty":30.707893,"marketCap":5392860036},{"date":"2021-07-30","current":16.221256,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5679061858},{"date":"2021-08-06","current":16.529487,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5786973465},{"date":"2021-08-13","current":17.085494,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5981631539},{"date":"2021-08-20","current":16.514415,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5781696589},{"date":"2021-08-27","current":17.391968,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":6088928007},{"date":"2021-09-03","current":16.290002,"twenty":15.768581,"median":21.108637,"eighty":30.707893,"marketCap":5703129776},{"date":"2021-09-10","current":15.723947,"twenty":15.757032,"median":21.108637,"eighty":30.707893,"marketCap":5504953785},{"date":"2021-09-17","current":15.378954,"twenty":15.742757,"median":21.108637,"eighty":30.707893,"marketCap":5384171968},{"date":"2021-09-24","current":15.594993,"twenty":15.679949,"median":21.108637,"eighty":30.707893,"marketCap":5459807184},{"date":"2021-10-01","current":16.263207,"twenty":15.679949,"median":21.108637,"eighty":30.707893,"marketCap":5693748664},{"date":"2021-10-08","current":16.043818,"twenty":15.679949,"median":21.108637,"eighty":30.707893,"marketCap":5616940810},{"date":"2021-10-15","current":15.605042,"twenty":15.643409,"median":21.108637,"eighty":30.707893,"marketCap":5463325101},{"date":"2021-10-22","current":15.794285,"twenty":15.639757,"median":21.108637,"eighty":30.707893,"marketCap":5529579204},{"date":"2021-10-29","current":14.76593,"twenty":15.597281,"median":21.108637,"eighty":30.707893,"marketCap":6055507796},{"date":"2021-11-05","current":15.208034,"twenty":15.546124,"median":21.108637,"eighty":30.707893,"marketCap":6236814727},{"date":"2021-11-12","current":15.298251,"twenty":15.518993,"median":21.108637,"eighty":30.707893,"marketCap":6273812781},{"date":"2021-11-19","current":14.851461,"twenty":15.463133,"median":21.108637,"eighty":30.707893,"marketCap":6090584325},{"date":"2021-11-26","current":14.333071,"twenty":15.432575,"median":21.108637,"eighty":30.707893,"marketCap":5877992336},{"date":"2021-12-03","current":14.039507,"twenty":15.386249,"median":21.108637,"eighty":30.707893,"marketCap":5757601844},{"date":"2021-12-10","current":14.812797,"twenty":15.373275,"median":21.108637,"eighty":30.707893,"marketCap":6074728017},{"date":"2021-12-17","current":13.748807,"twenty":15.338429,"median":21.108637,"eighty":30.707893,"marketCap":5638385894},{"date":"2021-12-23","current":14.274358,"twenty":15.317813,"median":21.108637,"eighty":30.707893,"marketCap":5853914237},{"date":"2021-12-31","current":14.567922,"twenty":15.293897,"median":21.108637,"eighty":30.707893,"marketCap":5974304729},{"date":"2022-01-07","current":15.013279,"twenty":15.255263,"median":21.086933,"eighty":30.706604,"marketCap":6156945913},{"date":"2022-01-14","current":15.296819,"twenty":15.234158,"median":21.086933,"eighty":30.706604,"marketCap":6273225510},{"date":"2022-01-21","current":14.26147,"twenty":15.159469,"median":21.086933,"eighty":30.706604,"marketCap":5848628801},{"date":"2022-01-28","current":13.473236,"twenty":15.141331,"median":21.086933,"eighty":30.706604,"marketCap":5866246922},{"date":"2022-02-04","current":13.791554,"twenty":15.108005,"median":21.086933,"eighty":30.706604,"marketCap":6004842805},{"date":"2022-02-11","current":13.714672,"twenty":15.072408,"median":21.086933,"eighty":30.706604,"marketCap":5971368375},{"date":"2022-02-18","current":13.760532,"twenty":15.03684,"median":21.086933,"eighty":30.706604,"marketCap":5991335579},{"date":"2022-02-25","current":13.698487,"twenty":15.01748,"median":21.086933,"eighty":30.706604,"marketCap":5964321127},{"date":"2022-03-04","current":13.275413,"twenty":15.000697,"median":21.086933,"eighty":30.706604,"marketCap":5780114910},{"date":"2022-03-11","current":13.404745,"twenty":14.95296,"median":21.086933,"eighty":30.706604,"marketCap":5836425811},{"date":"2022-03-18","current":14.316596,"twenty":14.909849,"median":21.086933,"eighty":30.706604,"marketCap":6233446103},{"date":"2022-03-25","current":14.323128,"twenty":14.844637,"median":21.086933,"eighty":30.706604,"marketCap":6236290088},{"date":"2022-04-01","current":14.200329,"twenty":14.811668,"median":21.086933,"eighty":30.706604,"marketCap":6182823172},{"date":"2022-04-08","current":13.370779,"twenty":14.787157,"median":21.086933,"eighty":30.706604,"marketCap":5821637090},{"date":"2022-04-14","current":13.605352,"twenty":14.765711,"median":21.086933,"eighty":30.706604,"marketCap":5923770233},{"date":"2022-04-22","current":13.520383,"twenty":14.746344,"median":21.086933,"eighty":30.706604,"marketCap":5886774696},{"date":"2022-04-29","current":12.486253,"twenty":14.722676,"median":21.019089,"eighty":30.706604,"marketCap":5394061408},{"date":"2022-05-06","current":12.456696,"twenty":14.697062,"median":20.987955,"eighty":30.706604,"marketCap":5381292864},{"date":"2022-05-13","current":11.781959,"twenty":14.669658,"median":20.987955,"eighty":30.706604,"marketCap":5089806167},{"date":"2022-05-20","current":11.653499,"twenty":14.65307,"median":20.987955,"eighty":30.706604,"marketCap":5034311584},{"date":"2022-05-27","current":12.38533,"twenty":14.632214,"median":20.987955,"eighty":30.706604,"marketCap":5350462540},{"date":"2022-06-03","current":12.325642,"twenty":14.611294,"median":20.987955,"eighty":30.706604,"marketCap":5324677178},{"date":"2022-06-10","current":11.976595,"twenty":14.57907,"median":20.987955,"eighty":30.706604,"marketCap":5173888868},{"date":"2022-06-17","current":10.930751,"twenty":14.551074,"median":20.987955,"eighty":30.706604,"marketCap":4722084488},{"date":"2022-06-24","current":11.496493,"twenty":14.512301,"median":20.989133,"eighty":30.707893,"marketCap":4966484872},{"date":"2022-07-01","current":11.448483,"twenty":14.475592,"median":20.989133,"eighty":30.707893,"marketCap":4945744472},{"date":"2022-07-08","current":11.682046,"twenty":14.446312,"median":20.989133,"eighty":30.707893,"marketCap":5046643714},{"date":"2022-07-15","current":11.634035,"twenty":14.405366,"median":20.901381,"eighty":30.707893,"marketCap":5025903314},{"date":"2022-07-22","current":12.2945,"twenty":14.378471,"median":20.826627,"eighty":30.707893,"marketCap":5311223946},{"date":"2022-07-29","current":10.048078,"twenty":14.354753,"median":20.788925,"eighty":30.707893,"marketCap":5545534406},{"date":"2022-08-05","current":10.145269,"twenty":14.322523,"median":20.788925,"eighty":30.707893,"marketCap":5599173918},{"date":"2022-08-12","current":10.721601,"twenty":14.301896,"median":20.788925,"eighty":30.707893,"marketCap":5917251426},{"date":"2022-08-19","current":10.554902,"twenty":14.25908,"median":20.788925,"eighty":30.707893,"marketCap":5825250171},{"date":"2022-08-26","current":9.974504,"twenty":14.187553,"median":20.788925,"eighty":30.707893,"marketCap":5504928730},{"date":"2022-09-02","current":9.465258,"twenty":14.135304,"median":20.788925,"eighty":30.707893,"marketCap":5223876117},{"date":"2022-09-09","current":9.759015,"twenty":14.102002,"median":20.788925,"eighty":30.707893,"marketCap":5386000279},{"date":"2022-09-16","current":9.233506,"twenty":14.059394,"median":20.788925,"eighty":30.707893,"marketCap":5095971933},{"date":"2022-09-23","current":8.782199,"twenty":14.031264,"median":20.788925,"eighty":30.707893,"marketCap":4846895366},{"date":"2022-09-30","current":8.898075,"twenty":13.970918,"median":20.788925,"eighty":30.707893,"marketCap":4910847458},{"date":"2022-10-07","current":9.505917,"twenty":13.919195,"median":20.788925,"eighty":30.707893,"marketCap":5246315447},{"date":"2022-10-14","current":9.625859,"twenty":13.853034,"median":20.788925,"eighty":30.707893,"marketCap":5312511472},{"date":"2022-10-21","current":10.108676,"twenty":13.814554,"median":20.788925,"eighty":30.707893,"marketCap":5578978520},{"date":"2022-10-28","current":14.974971,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5630588980},{"date":"2022-11-04","current":15.463609,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5814316860},{"date":"2022-11-11","current":15.563653,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5851933626},{"date":"2022-11-18","current":15.647273,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5883374505},{"date":"2022-11-25","current":16.044465,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":6032718681},{"date":"2022-12-02","current":15.78614,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5935588822},{"date":"2022-12-09","current":14.866328,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5589739152},{"date":"2022-12-16","current":14.373571,"twenty":13.814554,"median":20.751188,"eighty":30.707893,"marketCap":5404462543},{"date":"2022-12-23","current":14.855875,"twenty":13.814554,"median":20.344302,"eighty":30.707893,"marketCap":5585809042},{"date":"2022-12-30","current":14.999223,"twenty":13.814554,"median":19.765377,"eighty":30.707893,"marketCap":5639707692},{"date":"2023-01-06","current":15.569626,"twenty":13.814554,"median":19.464991,"eighty":30.682769,"marketCap":5854179403},{"date":"2023-01-13","current":16.083288,"twenty":13.814554,"median":19.115452,"eighty":30.607602,"marketCap":6047316232},{"date":"2023-01-20","current":16.159441,"twenty":13.814554,"median":18.427296,"eighty":30.461812,"marketCap":6075949889},{"date":"2023-01-27","current":15.870494,"twenty":13.814554,"median":17.1977,"eighty":30.416074,"marketCap":6365655133},{"date":"2023-02-03","current":16.700552,"twenty":13.814554,"median":17.005108,"eighty":30.370928,"marketCap":6698591585},{"date":"2023-02-10","current":16.651561,"twenty":13.814554,"median":16.756543,"eighty":30.27693,"marketCap":6678941035},{"date":"2023-02-17","current":16.851727,"twenty":13.814554,"median":16.756543,"eighty":30.179893,"marketCap":6759227566},{"date":"2023-02-24","current":16.526982,"twenty":13.814554,"median":16.695284,"eighty":30.105575,"marketCap":6628972495},{"date":"2023-03-03","current":17.355997,"twenty":13.814554,"median":16.651561,"eighty":29.955493,"marketCap":6961490255},{"date":"2023-03-10","current":15.566371,"twenty":13.814554,"median":16.584753,"eighty":29.755722,"marketCap":6243671220},{"date":"2023-03-17","current":15.480547,"twenty":13.814554,"median":16.531531,"eighty":29.517526,"marketCap":6209247509},{"date":"2023-03-24","current":14.869936,"twenty":13.814554,"median":16.458394,"eighty":29.346477,"marketCap":5964331266},{"date":"2023-03-31","current":15.968755,"twenty":13.81764,"median":16.370108,"eighty":29.233228,"marketCap":6405067639},{"date":"2023-04-06","current":16.098193,"twenty":13.814554,"median":16.263207,"eighty":29.165128,"marketCap":6456985367},{"date":"2023-04-13","current":16.098193,"twenty":13.811468,"median":16.213847,"eighty":29.047766,"marketCap":6456985367},{"date":"2023-04-21","current":11.256514,"twenty":13.795287,"median":16.167243,"eighty":28.957812,"marketCap":4514987632},{"date":"2023-04-28","current":10.547063,"twenty":13.769342,"median":16.098193,"eighty":28.929603,"marketCap":4230427133},{"date":"2023-05-05","current":9.97455,"twenty":13.75401,"median":16.098193,"eighty":28.929603,"marketCap":4000792069},{"date":"2023-05-12","current":10.85153,"twenty":13.72131,"median":16.043818,"eighty":28.869244,"marketCap":4360144650},{"date":"2023-05-19","current":10.855892,"twenty":13.715462,"median":15.968755,"eighty":28.809081,"marketCap":4361897590},{"date":"2023-05-26","current":10.676792,"twenty":13.696628,"median":15.930768,"eighty":28.764729,"marketCap":4289934926},{"date":"2023-06-02","current":10.354878,"twenty":13.660339,"median":15.878021,"eighty":28.764729,"marketCap":4160590154},{"date":"2023-06-09","current":11.276849,"twenty":13.620925,"median":15.820484,"eighty":28.752181,"marketCap":4531038118},{"date":"2023-06-16","current":11.224609,"twenty":13.575222,"median":15.789127,"eighty":28.740612,"marketCap":4510047958},{"date":"2023-06-23","current":11.398273,"twenty":13.554976,"median":15.774827,"eighty":28.742195,"marketCap":4579826058},{"date":"2023-06-30","current":12.275063,"twenty":13.534076,"median":15.748467,"eighty":28.744691,"marketCap":4932120371},{"date":"2023-07-07","current":12.273651,"twenty":13.517745,"median":15.73232,"eighty":28.744691,"marketCap":4931553069},{"date":"2023-07-14","current":12.851119,"twenty":13.480736,"median":15.69546,"eighty":28.744691,"marketCap":5163579436},{"date":"2023-07-21","current":13.091142,"twenty":13.444539,"median":15.669077,"eighty":28.744691,"marketCap":5260020713},{"date":"2023-07-28","current":28.047249,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":5306539447},{"date":"2023-08-04","current":27.615476,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":5224848012},{"date":"2023-08-11","current":26.895854,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":5088695621},{"date":"2023-08-18","current":25.936359,"twenty":13.437725,"median":15.657467,"eighty":28.744691,"marketCap":4907159099},{"date":"2023-08-25","current":26.047301,"twenty":13.437725,"median":15.657467,"eighty":28.735863,"marketCap":4928149259},{"date":"2023-09-01","current":27.32163,"twenty":13.437725,"median":15.657467,"eighty":28.633914,"marketCap":5169252452},{"date":"2023-09-08","current":25.936359,"twenty":13.437725,"median":15.657467,"eighty":28.427306,"marketCap":4907159099},{"date":"2023-09-15","current":26.131256,"twenty":13.437725,"median":15.657467,"eighty":28.310023,"marketCap":4944033705},{"date":"2023-09-22","current":25.732466,"twenty":13.437725,"median":15.657467,"eighty":28.103852,"marketCap":4868582588},{"date":"2023-09-29","current":26.778916,"twenty":13.437725,"median":15.657467,"eighty":28.040876,"marketCap":5066570857},{"date":"2023-10-06","current":25.921367,"twenty":13.437725,"median":15.657467,"eighty":27.952179,"marketCap":4904322591},{"date":"2023-10-13","current":26.404113,"twenty":13.437725,"median":15.657467,"eighty":27.770815,"marketCap":4995658153},{"date":"2023-10-20","current":25.186753,"twenty":13.437725,"median":15.657467,"eighty":27.598634,"marketCap":4765333692},{"date":"2023-10-27","current":17.482305,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5309375955},{"date":"2023-11-03","current":18.634591,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5659325216},{"date":"2023-11-10","current":18.896496,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5738865978},{"date":"2023-11-17","current":19.770139,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6004191234},{"date":"2023-11-24","current":20.363168,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6184294245},{"date":"2023-12-01","current":19.770139,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6004191234},{"date":"2023-12-08","current":19.455852,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":5908742320},{"date":"2023-12-15","current":20.419291,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":6201338694},{"date":"2023-12-22","current":21.33222,"twenty":13.425722,"median":15.649693,"eighty":27.611266,"marketCap":6478595064},{"date":"2023-12-29","current":22.136644,"twenty":13.421721,"median":15.647273,"eighty":27.615476,"marketCap":6722898833},{"date":"2024-01-05","current":21.592254,"twenty":13.419632,"median":15.645413,"eighty":27.624048,"marketCap":6557567678},{"date":"2024-01-12","current":21.081538,"twenty":13.419632,"median":15.645413,"eighty":27.624048,"marketCap":6402463192},{"date":"2024-01-19","current":21.749398,"twenty":13.417543,"median":15.643553,"eighty":27.632621,"marketCap":6605292135},{"date":"2024-01-26","current":21.257389,"twenty":13.419632,"median":15.645413,"eighty":27.624048,"marketCap":6455869132},{"date":"2024-02-02","current":28.058844,"twenty":13.419632,"median":15.669077,"eighty":27.669555,"marketCap":7180258215},{"date":"2024-02-09","current":28.169854,"twenty":13.419632,"median":15.704121,"eighty":27.796495,"marketCap":7208665630},{"date":"2024-02-16","current":27.308418,"twenty":13.419632,"median":15.733099,"eighty":27.825797,"marketCap":6988224090},{"date":"2024-02-23","current":27.148564,"twenty":13.419632,"median":15.755466,"eighty":27.825797,"marketCap":6947317412},{"date":"2024-03-01","current":27.092062,"twenty":13.441726,"median":15.777181,"eighty":27.812943,"marketCap":6932858665},{"date":"2024-03-08","current":29.888075,"twenty":13.445242,"median":15.789127,"eighty":27.963376,"marketCap":7648358285},{"date":"2024-03-15","current":28.812755,"twenty":13.445242,"median":15.827779,"eighty":28.043716,"marketCap":7373184090},{"date":"2024-03-22","current":30.106708,"twenty":13.445242,"median":15.896443,"eighty":28.076477,"marketCap":7704306565},{"date":"2024-03-28","current":30.093322,"twenty":13.445242,"median":15.930965,"eighty":28.169854,"marketCap":7700881160},{"date":"2024-04-05","current":30.22941,"twenty":13.444539,"median":15.993577,"eighty":28.367293,"marketCap":7735706111},{"date":"2024-04-12","current":30.521665,"twenty":13.444539,"median":16.063876,"eighty":28.550678,"marketCap":7810494118},{"date":"2024-04-19","current":28.866298,"twenty":13.444539,"median":16.098193,"eighty":28.738359,"marketCap":7386885709},{"date":"2024-04-26","current":38.231767,"twenty":13.445242,"median":16.102434,"eighty":28.817217,"marketCap":8219830006},{"date":"2024-05-03","current":37.612546,"twenty":13.445242,"median":16.172772,"eighty":28.907655,"marketCap":8086697428},{"date":"2024-05-10","current":38.354269,"twenty":13.445242,"median":16.221256,"eighty":29.130483,"marketCap":8246167924},{"date":"2024-05-17","current":38.702534,"twenty":13.445242,"median":16.290002,"eighty":29.281518,"marketCap":8321044752},{"date":"2024-05-24","current":38.854069,"twenty":13.445242,"median":16.385606,"eighty":29.401797,"marketCap":8353624746},{"date":"2024-05-31","current":39.239552,"twenty":13.454387,"median":16.514415,"eighty":29.631749,"marketCap":8436503678},{"date":"2024-06-07","current":37.902323,"twenty":13.473236,"median":16.552178,"eighty":29.829217,"marketCap":8148999521},{"date":"2024-06-14","current":38.593535,"twenty":13.469601,"median":16.648062,"eighty":29.922236,"marketCap":8297610020},{"date":"2024-06-21","current":37.928908,"twenty":13.465967,"median":16.735546,"eighty":30.031355,"marketCap":8154715310},{"date":"2024-06-28","current":38.468585,"twenty":13.455063,"median":16.771844,"eighty":30.093322,"marketCap":8270745814},{"date":"2024-07-05","current":38.447317,"twenty":13.455063,"median":16.814111,"eighty":30.119103,"marketCap":8266173184},{"date":"2024-07-12","current":38.896605,"twenty":13.455063,"median":16.946902,"eighty":30.175867,"marketCap":8362770008},{"date":"2024-07-15","current":39.090676,"twenty":13.455063,"median":17.002596,"eighty":30.222173,"marketCap":8404495263},{"date":"2024-08-02","current":36.716509,"twenty":13.443132,"median":17.163621,"eighty":30.257604,"marketCap":8848678588},{"date":"2024-08-09","current":34.544426,"twenty":13.474636,"median":17.391968,"eighty":30.380644,"marketCap":8325206621},{"date":"2024-08-16","current":35.878536,"twenty":13.516412,"median":18.180924,"eighty":30.441623,"marketCap":8646727108},{"date":"2024-08-23","current":35.80732,"twenty":13.536427,"median":18.692584,"eighty":30.507515,"marketCap":8629564092},{"date":"2024-08-30","current":37.015615,"twenty":13.564424,"median":19.093862,"eighty":30.613864,"marketCap":8920763252},{"date":"2024-09-06","current":35.370529,"twenty":13.617967,"median":19.465206,"eighty":30.68362,"marketCap":8524297599},{"date":"2024-09-13","current":35.593672,"twenty":13.654447,"median":19.770139,"eighty":30.724008,"marketCap":8578075046},{"date":"2024-09-20","current":36.657162,"twenty":13.697093,"median":19.955344,"eighty":30.811628,"marketCap":8834376075},{"date":"2024-09-27","current":37.647062,"twenty":13.718449,"median":20.170481,"eighty":31.202877,"marketCap":9072941988},{"date":"2024-10-04","current":37.063092,"twenty":13.754547,"median":20.419291,"eighty":33.022546,"marketCap":8932205262},{"date":"2024-10-11","current":36.813837,"twenty":13.782708,"median":20.788925,"eighty":33.919642,"marketCap":8872134709},{"date":"2024-10-18","current":38.748534,"twenty":13.844231,"median":21.132049,"eighty":34.498848,"marketCap":9338396624},{"date":"2024-10-25","current":35.731356,"twenty":13.972834,"median":21.270485,"eighty":35.063709,"marketCap":8611256876},{"date":"2024-10-31","current":35.156674,"twenty":14.041756,"median":21.392084,"eighty":35.155808,"marketCap":9249721045},{"date":"2024-11-08","current":37.821894,"twenty":14.04673,"median":21.716135,"eighty":35.381924,"marketCap":9950940184},{"date":"2024-11-15","current":37.830595,"twenty":14.04673,"median":21.871932,"eighty":35.703819,"marketCap":9953229467},{"date":"2024-11-22","current":39.842745,"twenty":14.04673,"median":22.117001,"eighty":35.842453,"marketCap":10482626124},{"date":"2024-11-29","current":39.607813,"twenty":14.04673,"median":22.252579,"eighty":36.21515,"marketCap":10420815487},{"date":"2024-12-06","current":38.322212,"twenty":14.04673,"median":22.415358,"eighty":36.508084,"marketCap":10082573948},{"date":"2024-12-13","current":36.138213,"twenty":14.04673,"median":22.859046,"eighty":36.698326,"marketCap":9507963955},{"date":"2024-12-20","current":33.179809,"twenty":14.04673,"median":23.30284,"eighty":36.698326,"marketCap":8729607789},{"date":"2024-12-27","current":34.026,"twenty":14.04673,"median":23.434298,"eighty":36.698326,"marketCap":8952240545},{"date":"2025-01-03","current":32.842638,"twenty":14.04673,"median":23.518071,"eighty":36.698326,"marketCap":8640898079},{"date":"2025-01-10","current":33.425618,"twenty":14.045235,"median":23.729434,"eighty":36.704639,"marketCap":8794280029},{"date":"2025-01-17","current":33.814996,"twenty":14.045235,"median":23.80934,"eighty":36.704639,"marketCap":8896725436},{"date":"2025-01-24","current":35.437768,"twenty":14.045235,"median":23.953686,"eighty":36.704639,"marketCap":9323676686},{"date":"2025-01-31","current":33.333263,"twenty":14.045235,"median":23.956263,"eighty":36.531348,"marketCap":9823312666},{"date":"2025-02-07","current":33.556598,"twenty":14.045235,"median":23.956263,"eighty":36.222746,"marketCap":9889129548},{"date":"2025-02-14","current":32.746766,"twenty":14.045235,"median":23.956263,"eighty":35.878536,"marketCap":9650471812},{"date":"2025-02-21","current":33.306075,"twenty":14.045235,"median":23.956263,"eighty":35.814441,"marketCap":9815300176},{"date":"2025-02-28","current":31.197014,"twenty":14.045235,"median":23.956263,"eighty":35.764062,"marketCap":9193759885},{"date":"2025-03-07","current":29.524826,"twenty":14.045214,"median":23.954974,"eighty":35.772714,"marketCap":8700966306},{"date":"2025-03-14","current":29.365117,"twenty":14.045214,"median":23.967817,"eighty":35.772714,"marketCap":8653899927},{"date":"2025-03-21","current":29.877642,"twenty":14.045214,"median":24.116075,"eighty":35.772714,"marketCap":8804941148},{"date":"2025-03-28","current":30.412112,"twenty":14.045214,"median":24.170205,"eighty":35.772714,"marketCap":8962449399},{"date":"2025-04-04","current":28.45369,"twenty":14.045214,"median":24.30281,"eighty":35.772714,"marketCap":8385302378},{"date":"2025-04-11","current":27.414009,"twenty":14.045235,"median":24.43312,"eighty":35.764062,"marketCap":8078908592},{"date":"2025-04-17","current":27.614923,"twenty":14.045235,"median":24.592932,"eighty":35.764062,"marketCap":8138117897},{"date":"2025-04-25","current":29.14811,"twenty":14.045214,"median":24.78754,"eighty":35.772714,"marketCap":8589948135},{"date":"2025-05-02","current":27.818973,"twenty":14.045214,"median":24.78754,"eighty":35.772714,"marketCap":9374993854},{"date":"2025-05-09","current":28.96729,"twenty":14.045214,"median":24.78754,"eighty":35.772714,"marketCap":9761976856},{"date":"2025-05-16","current":30.05077,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":10127109406},{"date":"2025-05-23","current":29.127679,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":9816027974},{"date":"2025-05-30","current":29.564484,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":9963231018},{"date":"2025-06-06","current":29.840899,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":10056382944},{"date":"2025-06-10","current":31.734855,"twenty":14.045214,"median":24.915132,"eighty":35.772714,"marketCap":10694646142}],"updateTime":1749699397953}}}